OKYO Pharma Ltd

OKYO Pharma Ltd operates in the biotechnology and pharmaceutical industry, specifically focused on the development of therapies for ophthalmic diseases. The company is a clinical-stage biopharmaceutical company with no products approved for commercial sale and no revenue from product sales. The industry is characterized by a high degree of failure for product candidates as they progress through clinical trials, with many companies in the life sciences and biotechnology sector suffering significant setbacks in later stage clinical trials. The company sits within the competitive landscape of ocular surface disease, a market addressed by a number of large and small pharmaceutical companies with established products.

The company faces significant competition from major multinational pharmaceutical companies, universities, and research institutions internationally. Many competitors have substantially greater financial, technical, and other resources, including larger research and development teams, proven marketing and manufacturing organizations, and well-established sales forces. Competitors may succeed in developing, acquiring, or licensing drug products that are more effective or less costly than products OKYO is currently developing. The availability and price of competitors' products could limit demand and the price OKYO is able to charge for any of its products, if approved for sale. Competition from lower-cost generic pharmaceuticals may also result in significant reductions in sales volumes or prices.

OKYO Pharma currently generates no revenue from sales of any product and may never be able to develop or commercialize a marketable product. The company's business model is centered on the research and development of product candidates for ophthalmic diseases, with the expectation that any product revenue will not occur for several years, if ever. The company relies on third parties for the conduct of clinical trials, other product development, manufacture, and protection of intellectual property rights. OKYO's strategy utilizes the expertise and resources of third parties, including independent clinical investigators and contract research organizations (CROs), to conduct preclinical studies and clinical trials, and contract manufacturing organizations (CMOs) for the manufacturing of clinical batches.

OKYO Pharma's primary product candidate is urcosimod (formally known as OK-101), which is in the mid stage of development. The company is developing urcosimod for the initial indications of neuropathic corneal pain (NCP) and other Corneal and Anterior Segment Diseases. The commercial development of urcosimod is highly dependent on several factors, including the successful conduct of further human trials, receipt of marketing approvals in the United States and other jurisdictions, launching commercial sales if approved, acceptance by patients and the medical community, and competing effectively with existing therapies. The company's second product candidate is OK-201, which is in the early stage of development.

OKYO Pharma has invested and continues to invest resources into the development of OK-201. Even if OK-201 is successfully developed and marketing approval is secured, the product might not achieve commercial success due to factors such as limited market acceptance, new competitor products, relative efficacy or cost of competitive products, inability to supply sufficient product, insufficient funding for marketing, inability to enforce intellectual property rights, safety concerns, labelling restrictions, or refusal by government or healthcare payors to fund the product at a commercially viable level.

As of March 31, 2026, the company's cash and cash equivalents, plus cash classified as a short term investment balance, was approximately $20.6 million ¹, and its working capital surplus was approximately $12.3 million ². The company has historically relied upon private and public sales of its equity, as well as debt financings, to fund its operations. Due to recurring losses from operations and the expectation of continuing losses, the company will be required to raise additional capital to complete the development and commercialization of its current product candidates. If unable to raise additional capital when required or on acceptable terms, the company may have to significantly delay, scale back, or discontinue the development and/or commercialization of its product candidate.

OKYO Pharma has incurred losses since inception and anticipates continuing to incur significant losses for the foreseeable future. The amount of future net losses will depend on the rate of future expenditures, including further research and development activity, and on the success in developing and commercializing urcosimod and other products that may generate significant revenue. As of March 31, 2026, the company had cumulative carryforward tax losses of $45,018,522 ³. The company benefits from the U.K. research and development tax credit regime for small and medium-sized companies, whereby it is able to surrender trading losses from qualifying research and development activities for a payable tax credit of up to 33.35% ⁴ of eligible research and development expenditures, with certain subcontracted qualifying research expenditures eligible for a cash rebate of up to 21.67% ⁵.

A primary growth vector for OKYO is the continued clinical development of urcosimod for neuropathic corneal pain (NCP) and other Corneal and Anterior Segment Diseases. The company intends to conduct further human trials in these initial indications. Successful completion of one stage of development does not ensure subsequent stages will be successful, and there is a high failure rate for product candidates as they proceed through clinical trials. The company also plans to continue investing resources into the development of OK-201, its early-stage product candidate. The commercial success of any product will depend on factors including market acceptance, competition, and the ability to secure adequate pricing and reimbursement.

Another growth vector involves the potential for future acquisitions and strategic partnerships, including licensing or acquiring complementary drugs, intellectual property rights, technologies, or businesses. The company intends to continue evaluating such opportunities. Any potential acquisition or strategic partnership may entail risks including increased operating expenses, cash requirements, assumption of indebtedness or contingent liabilities, and difficulties assimilating operations. The company may also seek to enter into arrangements with third parties to perform sales and marketing services in non-core territories, though such arrangements could result in lower product revenues or profitability.

The filing does not contain specific margin or cost outlook targets or restructuring targets.

The company relies on third-party contract manufacturing organizations (CMOs) for the manufacturing of clinical batches and intends to continue relying on third parties to manufacture preclinical study and clinical trial product supplies. The company does not currently operate manufacturing facilities for clinical or commercial production. Before commercial manufacturing can begin, regulatory approval must be obtained for the manufacturing process and facility. The company also relies on third-party CROs to conduct preclinical studies and clinical trials and to monitor and manage data. There is a limited number of qualified third-party service providers that specialize or have the expertise required to achieve the company's business objectives.

The company expects to incur further significant expenses in connection with its ongoing research and development activities, including funding future clinical studies, registration, manufacturing, marketing, sales, and distribution. The company benefits from the U.K. research and development tax credit regime, which provides a payable tax credit of up to 33.35% ⁶ of eligible research and development expenditures for small and medium-sized companies, and up to 21.67% ⁷ for certain subcontracted qualifying research expenditures. The company's ability to continue to claim payable research and development tax credits in the future may be limited if it no longer qualifies as a small or medium-sized company. The company may also benefit in the future from the United Kingdom's "patent box" regime, which allows certain profits attributable to revenues from patented products to be taxed at an effective rate of 10% ⁸.

A significant headwind is the company's need to raise substantial additional capital to develop and commercialize its product candidates. As of March 31, 2026, cash and cash equivalents plus short-term investments were approximately $20.6 million ⁹, and the company has recurring losses from operations. Access to adequate additional financing may not be available on acceptable terms or at all. If unable to raise capital, the company could be forced to delay, reduce, or eliminate research and development programs or commercialization efforts. Any additional equity fundraising may be dilutive for shareholders.

Regulatory and macro factors present constraints. The company must obtain regulatory approval from the FDA, EMA, MHRA, and other authorities before commercializing any product candidate, a process that is lengthy, expensive, and uncertain. The UK's exit from the EU (Brexit) could materially impact the regulatory regime, as the UK is no longer covered by centralized procedures for obtaining EU-wide marketing authorizations, requiring separate marketing authorization for products to be marketed in the UK. Healthcare legislative reform measures in the United States, including the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act enacted in July 2025, could negatively impact the pharmaceutical industry and the company's ability to receive adequate revenues for product candidates if approved.

The company's product candidates are in early to mid stages of development, and there is a high failure rate for pharmaceutical products as they progress through clinical trials, with no guarantee that urcosimod or OK-201 will ever receive regulatory approval or become commercially viable. The company has no revenue from product sales and will need to raise substantial additional capital to fund development; as of March 31, 2026, cash and short-term investments were approximately $20.6 million ¹⁰ with a working capital surplus of $12.3 million ¹¹, and failure to obtain funding may force delay or reduction of programs. The company faces intense competition from major multinational pharmaceutical companies with greater resources, and competitors may develop more effective or less costly products. The company relies entirely on third-party CROs and CMOs for clinical trials and manufacturing, and any failure by these parties to perform could delay or prevent regulatory approval. The company's commercial success depends on obtaining and maintaining adequate intellectual property protection, and third parties may have blocking patents or challenge the company's patents, which could prevent commercialization or require costly licenses.

Management's message emphasizes the significant risks and uncertainties inherent in the development of pharmaceutical products, particularly for a clinical-stage company with no approved products or revenue. The forward-looking statements in the filing caution that actual results may differ materially from expectations due to known and unknown risks. Management highlights that the company's product candidates urcosimod is in the mid stage and OK-201 is in the early stage of development, and that the ability to generate product revenue is not expected for several years, if ever. The strategic priorities emphasized include the continued development of urcosimod for neuropathic corneal pain and other ocular diseases, the need to raise substantial additional capital to fund operations and development, and the reliance on third parties for clinical trials, manufacturing, and intellectual property protection. Management also underscores the importance of obtaining and maintaining intellectual property protection and navigating the complex regulatory landscape in the United States, European Union, and United Kingdom.